Pentoxifylline as a Novel Add-on Therapy for Major Depressive Disorder in Adult Patients: A Randomized, Double-Blind, Placebo-Controlled Trial [0.03%]
匹诺卡品作为成人抑郁症增效治疗的新药 III 期随机双盲安慰剂对照试验
Talar A Merza Mohammad,Tavgah A Merza Mohammad,Dyar M Salman et al.
Talar A Merza Mohammad et al.
Background: Evidence indicates an association between immune dysregulation and major depressive disorder (MDD). Pentoxifylline (PTX), a phosphodiesterase inhibitor, has been shown to reduce pro-inflammatory activities. Th...
Randomized Controlled Trial
Pharmacopsychiatry. 2024 Jul;57(4):205-214. DOI:10.1055/a-2291-7204 2024
Risk Phenotypes, Comorbidities, Pharmacotherapy, and Electroconvulsive Therapy (ECT) in a Cohort with Difficult-to-Treat Depression in Comparison to an Unmedicated Control Group [0.03%]
难治性抑郁患者的危险表型、共病、药物治疗和电休克治疗与其未用药对照组的比较研究
Hannah B Maier,Anton Borchert,Alexandra Neyazi et al.
Hannah B Maier et al.
Background: Approximately 15-25% of depressed patients suffer from difficult-to-treat depression (DTD). Patients with DTD require a thorough examination to avoid the oversight of treatable (psychiatric/somatic) comorbidit...
Blood Cell Count Ratios at Baseline are Associated with Initial Clinical Response to Clozapine in Treatment-Resistant, Clozapine-Naïve, Schizophrenia-Spectrum Disorder [0.03%]
基线血细胞计数比值与难治性精神分裂症谱系障碍氯氮平初治的初始临床反应有关
Vicent Llorca-Bofí,Miquel Bioque,Santiago Madero et al.
Vicent Llorca-Bofí et al.
Background: Clozapine is the recommended treatment for managing treatment-resistant schizophrenia (TRS), and immunological mechanisms may be involved in its unique antipsychotic efficacy. This study investigated whether b...
Comparable Psychotropic Prescription Rates After Hospital Discharge Between Patients with COVID-19 and Those With Non-COVID-19-Related Respiratory Infection [0.03%]
出院后新冠肺炎患者和非新冠肺炎呼吸系统感染患者的 psychotropic药物开具处方率可比性研究
Yuna Takahashi,Taisuke Yatomi,Naohito Yamaguchi et al.
Yuna Takahashi et al.
Introduction: Whether psychiatric symptoms after recovery from coronavirus disease 2019 (COVID-19) are specific to this illness remains unclear. Methods: ...
Comparative Study
Pharmacopsychiatry. 2024 Jul;57(4):186-190. DOI:10.1055/a-2286-1427 2024
Medicinal Use of Different Cannabis Strains: Results from a Large Prospective Survey in Germany [0.03%]
不同种类的大麻的药用价值：来自德国一项大规模前瞻性调查的结果
Natalia Szejko,Eva Becher,Florian Heimann et al.
Natalia Szejko et al.
Background: Up to now, it is unclear whether different medicinal cannabis (MC) strains are differently efficacious across different medical conditions. In this study, the effectiveness of different MC strains was compared...
Risperidone-Induced Leukoneutropenia: Evidence from a Positive Rechallenge and Review of the Literature [0.03%]
利培酮引起的白细胞中性粒细胞减少症：阳性再激发证据和文献回顾
Dhouha Sahnoun,Ahlem Ghanmi,Soumaya Gazzeh et al.
Dhouha Sahnoun et al.
Antipsychotics can cause hematologic disorders, and they can have life-threatening consequences. Risperidone, less commonly associated with hematologic adverse effects, is an atypical antipsychotic medication used to treat conditions such a...
Scott Monteith,Tasha Glenn,John R Geddes et al.
Scott Monteith et al.
Online self-diagnosis of psychiatric disorders by the general public is increasing. The reasons for the increase include the expansion of Internet technologies and the use of social media, the rapid growth of direct-to-consumer e-commerce i...
Perceptions, Experiences, and Patterns of Cannabis Use in Individuals with Mood and Anxiety Disorders in the Context of Cannabis Legalization and Medical Cannabis Program in Canada - A Qualitative Study [0.03%]
加拿大合法化大麻和医疗大麻项目的背景下，患有情绪障碍和焦虑障碍个体对大麻使用感知、体验与模式的一项定性研究
Ankita Das,Christian S Hendershot,M Ishrat Husain et al.
Ankita Das et al.
Introduction: Perceptions of cannabis as a potential medical treatment for mood and anxiety disorders have been increasing in the context of legalizations, availability, and medical cannabis programs, though current evide...
Barbara Broers,Federica Bianchi
Barbara Broers
Dementia, with loss of memory, cognitive abilities, and independent daily functioning, is increasing worldwide, related to an aging population. Currently, there is no curative treatment for dementia. Treatment of the frequently occurring be...
Cannabinoids in the Treatment of Selected Mental Illnesses: Practical Approach and Overview of the Literature [0.03%]
大麻素在治疗某些精神疾病中的应用：实用方法和文献综述
Kirsten R Müller-Vahl
Kirsten R Müller-Vahl
Although an increasing number of patients suffering from mental illnesses self-medicate with cannabis, current knowledge about the efficacy and safety of cannabis-based medicine in psychiatry is still extremely limited. So far, no cannabis-...